Frontiers in Aging Neuroscience (Jul 2021)

The Multi-Domain Intervention Trial in Older Adults With Diabetes Mellitus for Prevention of Dementia in Japan: Study Protocol for a Multi-Center, Randomized, 18-Month Controlled Trial

  • Taiki Sugimoto,
  • Taiki Sugimoto,
  • Atsushi Araki,
  • Hiroki Fujita,
  • Keiko Honda,
  • Nobuya Inagaki,
  • Takeshi Ishida,
  • Junichi Kato,
  • Minoru Kishi,
  • Kazuki Kobayashi,
  • Kunichi Kouyama,
  • Hisashi Noma,
  • Mitsuru Ohishi,
  • Noriko Satoh-Asahara,
  • Hiroyuki Shimada,
  • Kazuhiro Sugimoto,
  • Susumu Suzuki,
  • Yasushi Takeya,
  • Yoshiaki Tamura,
  • Haruhiko Tokuda,
  • Haruhiko Tokuda,
  • Hiroyuki Umegaki,
  • Hirotaka Watada,
  • Yuichiro Yamada,
  • Takashi Sakurai,
  • Takashi Sakurai

DOI
https://doi.org/10.3389/fnagi.2021.680341
Journal volume & issue
Vol. 13

Abstract

Read online

Background: The Japan-Multi-domain Intervention Trial for Prevention of Dementia in Older Adults with Diabetes (J-MIND-Diabetes) is an 18-month, multi-centered, open-labeled, randomized controlled trial designed to identify whether multi-domain intervention targeting modifiable risk factors for dementia could prevent the progression of cognitive decline among older adults with type 2 diabetes mellitus (T2DM). This manuscript describes the study protocol for the J-MIND-Diabetes trial.Materials and Methods: Subjects of this trial will comprise a total of 300 T2DM outpatients aged 70–85 years with mild cognitive impairment. Subjects will be centrally randomized into intervention and control groups at a 1:1 allocation ratio using the stratified permuted-block randomization methods. The intervention group will participate in multi-domain intervention programs aimed at: (1) management of metabolic and vascular risk factors; (2) physical exercise and self-monitoring of physical activity; (3) nutritional guidance; and (4) social participation. The control group will receive usual T2DM care and general instructions on dementia prevention. The primary and secondary outcomes will be assessed at baseline, at 6- and 18-month follow-up. The primary outcome is change from baseline at 18 months in a global composite score combining several neuropsychological domains, including global cognitive function, memory, attention, executive function, processing speed and language. Secondary outcomes include: (1) cognitive changes in neuropsychological tests; (2) changes in geriatrics assessments; (3) metabolic control and diabetic complications; (4) changes in blood and urinary markers.Discussion: This trial will be the first trial to demonstrate the effectiveness of multi-domain intervention in preventing cognitive decline in older adults with T2DM at increased risk of dementia in Japan.Trial Registration: UMIN000035911; Registered on the University Hospital Medical Information Network Clinical Trials Registry (UMIN-CTR) 18 February 2019. (https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000040908).

Keywords